Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1020 | Interdisciplinary Endocrinology 2 | ECE2019

Circulating miRNAs expression profile in in vitro muscle cell model exposed to cortisol excess

Patalano Roberta , Pivonello Claudia , Monto Tatiana , Simeoli Chiara , Negri Mariarosaria , Di Gennaro Gilda , Papa Fortuna , de Angelis Cristina , Cristina De Martino Maria , Pivonello Rosario

Cushing’s Syndrome (CS) is associated with a severe myopathy mainly affecting type 2 muscle fibres, with a higher prevalence in male subjects. The excess of glucocorticoids (GC) levels represents the most common cause of myopathy due to an alteration of protein metabolism. The non-coding post-transcriptional gene regulators muscle-specific microRNAs (miRNA) control muscle development and differentiation but when dysregulated lead to skeletal muscle (SM) disorder. The aim ...

ea0049gp177 | Pituitary | ECE2017

Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Ferone Diego , Borson-Chazot Francoise , Cailleux Anne , Horsch Dieter , lahner Harald , Pivonello Rosario , Tauchmanova Libuse , Darstein Christelle , Olsson Hakan , Tiberg Fredrik , Pavel Marianne

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

ea0049gp184 | Pituitary | ECE2017

Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

Auriemma Renata Simona , Blasio Chiara , Grasso Ludovica Francesca Stella , Galdiero Mariano , Negri Mariarosaria , Pivonello Claudia , Granieri Luciana , Colao Annamaria , Pivonello Rosario

Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, wais...

ea0049gp187 | Pituitary & endocrine Tumours | ECE2017

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

Pivonello Rosario , Kadioglu Pritam , Bex Marie , Devia Deyanira Gonzalez , Boguszewski Cesar , Yavuz Dilek Gogas , Patino Heather , Campigotto Federico , Pedroncelli Alberto , Fleseriu Maria , Biller Beverly M K , Feelders Richard

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

ea0049ep786 | Endocrine tumours and neoplasia | ECE2017

Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1,25(OH)vitamin D (VitD) reverts everolimus (EVE) resistance in a hcc cell line

Pivonello Claudia , Provvisiero Donatella Paola , Negri Mariarosaria , Gennaro Gilda Di , de Angelis Cristina , Simeoli Chiara , Galdiero Giacomo , Martino Maria Cristina De , Colao Annamaria , Pivonello Rosario

HCC is a difficult-to-treat- cancer with poor prognosis. Despite EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced sorafenib resistant HCC, in selected patients, the established antitumor effect of EVE could make this drug a potential adjuvant therapy. Unfortunately, the acquired EVE resistance due to the tumour adaptation to chronic drug use is a current challenge. VitD has been deemed as pote...

ea0049ep927 | Pituitary - Basic | ECE2017

Ketoconazole induces inhibition of cell viability and apoptosis in an ACTH-secreting tumour cell line model

Patalano Roberta , Pivonello Claudia , Solari Domenico , Vitulli Francesca , Iacuaniello Davide , Leo Monica De , Negri Mariarosaria , Provvisiero Donatella Paola , Cavallo Luigi Maria , Cappabianca Paolo , Colpo Annamaria , Pivonello Rosario

Chronic cortisol excess as a consequence of ACTH overproduction from a pituitary tumour is responsible for the development of Cushing’s disease (CD). The first-line treatment for CD is pituitary surgery, but medical treatment is an alternative second-line approach to control cortisol excess. Among pharmacological agents, the adrenal-blocking drug ketoconazole (KT), is able to control cortisol excess in the majority of patients with CD. During KT treatment, the adrenal blo...

ea0049ep1056 | Pituitary - Clinical | ECE2017

Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing’s disease: an Italian, multicenter study

Albani Adriana , Ferrau Francesco , Messina Erika , Pivonello Rosario , Scaroni Carla , Giordano Carla , Cozzolino Alessia , Zilio Marialuisa , Guarnotta Valentina , Ciresi Alessandro , Iacuaniello Davide , Alibrandi Angela , Colao Annamaria , Cannavo Salvatore

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of vi...

ea0041oc8.2 | Thyroid - Translational | ECE2016

Selenium modulates apoptosis in thyroid follicular cells: characterization of molecular mechanisms

Cristina Nettore Immacolata , Maione Luigi , Passaro Carmela , Pivonello Claudia , Negri Mariarosaria , Desiderio Silvio , De Nisco Emma , Pivonello Rosario , Ungaro Paola , Portella Giuseppe , Colao Annamaria , Emidio Macchia Paolo

: Inflammation and several oxidative processes are modulated by Selenium (Se) trough the selenoproteins. Se deficiency has been associated with thyroid autoimmune diseases and hypothyroidism, while Se-supplementation reduces antibodies titles and ameliorates ultrasound pattern of the gland.Aim of the current study, is to study the molecular effects of Se-supplementation in thyroid follicular cells (FRTL5).FRTL5 cells have been star...

ea0041gp17 | Adrenal (1) | ECE2016

Improved evening and nocturnal cortisol exposure time profile in patients with adrenal insufficiency treated with dual release hydrocortisone: correlation with improvement in metabolic profile

Simeoli Chiara , Ferrigno Rosario , De Martino Maria Cristina , Auriemma Renata Simona , Pivonello Claudia , Negri Mariarosaria , Iacuaniello Davide , Di Gennaro Gilda , Colao Annamaria , Pivonello Rosario

Conventional glucocorticoids (GCs) are unable to mimic physiological cortisol rhythm in adrenal insufficiency (AI), with a significant impact on morbidity and mortality. Possible explanations are supra-physiological doses and impaired cortisol profile. In particular, elevated evening cortisol levels were related to glucose tolerance and insulin sensitivity alterations and visceral obesity. Once-daily-dual-release-hydrocortisone (OD-DR-HC), better reproducing the physiological ...

ea0041ep583 | Endocrine Disruptors | ECE2016

Thyroid diseases in the ‘Land of Fires’: results of a single center screening in Acerra (Naples)

Simona Auriemma Renata , Cozzolino Mariaconcetta , Belli Arturo , Fierro Gaetano , Messina Gaetana , De Luca Renato , De Simone Teresa , Rivezzi Matteo , Galdiero Mariano , de Angelis Cristina , Pivonello Rosario , Colao Annamaria

Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’.Methods: The screening included subjects aged &#...